Joe Frumkin Named Dealmaker of the Week by The American Lawyer for Advising Teva in its Acquisition of Allergan Generics

July 31, 2015

On July 31, Mr. Frumkin was named Dealmaker of the Week by The American Lawyer for his role advising Israel's Teva Pharmaceutical Industries Ltd., the world's largest generic drug maker, in its $40.5 billion acquisition of the generics business of Allergan plc. The deal offered multiple layers of complexity surrounding the contractual framework and short timeline. In addition to these challenges, there is a large amount of sensitivity surrounding a simultaneous deal in which S&C stepped in mid-bid advising Teva in its existing bid for Mylan NV. AmLaw reported, “Frumkin said the greatest challenge, however, was working on Teva's bid for Mylan and a possible simultaneous acquisition of Allergan's generics unit.” Mr. Frumkin told AmLaw, “as the probability of Allergan seemed to increase as it firmed up, we migrated resources over to Allergan from Mylan… [o]verall it was the combination that made it really one of the most challenging client representations of my career.”